Imatinib

An orally bioavailability mesylate salt of Imatinib, which is a multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 uM, 0.1 uM and 0.1 uM in cell-free or cell-based assays; inhibits the SLF-dependent activation of wild-type c-kit kinase activity with IC50 of 0.1 uM; exhibits growth-inhibitory activity on NCI-H727 cell and BON-1 cell with IC50 of 32.4 and 32.8 uM, respectively; active in vivo.Blood Cancer Approved (In Vitro) :Imatinib (STI571) inhibits c-Kit autophosphorylation, activation of MAPK, and activation of Akt without altering total protein levels of c-kit, MAPK, or Akt. The concentration that produces 50% inhibition for these effects is approximately 100 nM.Imatinib (STI571) is very effective (in vitro IC50 of 25 nM) against the chronic myeloid leukemia-causing kinase Bcr-Abl. Imatinib also efficiently inhibits Kit (in vitro IC50, 410 nM) and PDGFR (in vitro IC50, 380 nM) .Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and inhibits Bcr/Abl, v-Abl, Tel/Abl, the native PDGFβ receptor, and c-Kit, but it does not inhibit Src family kinases, c-Fms, Flt3, the EGFR or multiple other tyrosine kinases. Imatinib inhibits tyrosine phosphorylation and cell growth of Ba/F3 cells expressing Bcr/Abl, Tel/Abl, Tel/PDGFβR, and Tel/Arg with an IC50 of approximately 0.5 μM in each case, but it has no effect on untransformed Ba/F3 cells growing in IL-3 or on Ba/F3 cells transformed by Tel/JAK2.The IC50s of Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and on BON-1 and H727 cells after exposure for 48 h are 32.4 and 32.8 μM, respectively. (In Vivo) :n the phosphorothioate antisense oligodeoxynucleotides (PS-ASODN) group, tumor growth is inhibited by 59.437%, which is markedly higher than in the Imatinib (STI571) is a multi-target inhibitor of v-Abl, c-Kit and group (11.071%) and liposome negative control group (2.759%) . Telomerase activity is significantly lower (P<0.01) in the PS-ASODN group (0.689±0.158) compare with the Imatinib group (1.838±0.241), liposome negative control group (2.013±0.273), and saline group (2.004±0.163) .Imatinib (25 mg/kg/day, p.o.) suppresses the growth of endometriotic tissue and reduces the number of ovarian follicles in a rat model. Imatinib effectively treats experimental endometriosis by its inhibitor effects on angiogenesis and cell proliferation.

152459-95-5

STI571 | STI 571 | STI-571

Pharmacology & Drug Discovery

>98% (HPLC)

DMSO: 40 mg/mL

CC1=C (C=C (C=C1) NC (=O) C2=CC=C (C=C2) CN3CCN (CC3) C) NC4=NC=CC (=N4) C5=CN=CC=C5

C29H31N7O

493.6028

Storage temperature: -20°C. Stability: ≥ 2 years

For research use only.